Viridian Therapeutics Enters Autoinjector Pen Device Customization And Supply Agreement With Ypsomed AG For Subcutaneous Drug Delivery In Thyroid Eye Disease
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics (NASDAQ:VRDN) has signed a supply agreement with Ypsomed AG for the latter's YpsoMate 2.25 autoinjector pen device. The device will be used for the subcutaneous delivery of Viridian's investigational therapies for thyroid eye disease (TED). Viridian's lead product candidate, VRDN-001, is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated target for TED treatment. The company is also advancing three candidates designed for subcutaneous injection for TED treatment.
October 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics has entered into a supply agreement with Ypsomed AG for the supply of autoinjector pen devices. This supports Viridian's development of subcutaneous therapies for thyroid eye disease.
The partnership with Ypsomed AG will provide Viridian with the necessary delivery devices for its investigational therapies. This could potentially accelerate the development and approval process of these therapies, which would be positive for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100